U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2009
364
Substance Class Protein
Created
by admin
on Wed Apr 02 07:41:07 GMT 2025
Edited
by admin
on Wed Apr 02 07:41:07 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
37CQ2C7X93
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANAKINUMAB
DASH   EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ILARIS
Preferred Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION)
Common Name English
ACZ885
Code English
Canakinumab [WHO-DD]
Common Name English
canakinumab [INN]
Common Name English
CANAKINUMAB [MI]
Common Name English
CANAKINUMAB [MART.]
Common Name English
CANAKINUMAB [USAN]
Common Name English
CANAKINUMAB [PURPLE BOOK CDER]
Common Name English
CANAKINUMAB [EMA EPAR]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN-1 BETA (IL-1.BETA.)) HUMAN MONOCLONAL ACZ885; (1GLU>GLP)-.GAMMA.1 HEAVY CHAIN (221-214')-DISULPHIDE WITH KAPPA LIGHT CHAIN, DIMER (227-227'':230-230'')-BISDISULPHIDE
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN-1 BETA (IL-1.BETA.)) HUMAN MONOCLONAL ACZ885; (1GLU>GLP)-.GAMMA.1 HEAVY CHAIN (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN, DIMER (227-227'':230-230'')-BISDISULFIDE
Common Name English
ACZ-885
Code English
CANAKINUMAB [VANDF]
Common Name English
CANAKINUMAB [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 260408
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
FDA ORPHAN DRUG 376912
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
WHO-VATC QL04AC08
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
EU-Orphan Drug EU/3/12/1071
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
FDA ORPHAN DRUG 412813
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
FDA ORPHAN DRUG 250507
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
FDA ORPHAN DRUG 805920
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
WHO-ATC L04AC08
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
EMA ASSESSMENT REPORTS ILARIS (AUTHORIZED: ARTHRITIS, JUVENILE RHEUMATOID)
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
FDA ORPHAN DRUG 591317
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
FDA ORPHAN DRUG 412913
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
EMA ASSESSMENT REPORTS ILARIS (AUTHORIZED: ARTHRITIS, GOUTY)
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
NCI_THESAURUS C20401
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
Code System Code Type Description
CAS
914613-48-2
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
EPA CompTox
DTXSID601017652
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
MESH
C541220
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
INN
8836
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
DAILYMED
37CQ2C7X93
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201834
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
DRUG CENTRAL
4952
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
DRUG BANK
DB06168
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
LACTMED
Canakinumab
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
FDA UNII
37CQ2C7X93
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
RXCUI
853491
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY RxNorm
USAN
UU-146
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
NCI_THESAURUS
C80971
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
WIKIPEDIA
CANAKINUMAB
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
IUPHAR
6773
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
SMS_ID
100000093070
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
EVMPD
SUB30137
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY
MERCK INDEX
m3009
Created by admin on Wed Apr 02 07:41:07 GMT 2025 , Edited by admin on Wed Apr 02 07:41:07 GMT 2025
PRIMARY Merck Index
From To
1_22 1_96
2_22 2_96
2_145 2_201
2_221 4_214
2_262 2_322
1_145 1_201
2_368 2_426
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
1_221 3_214
1_227 2_227
1_230 2_230
1_262 1_322
1_368 1_426
Glycosylation Link Type Site
N 1_298
N 2_298
Related Record Type Details
INTERLEUKIN-1 .BETA. HUMAN
TARGET -> INHIBITOR
Related Record Type Details
CANAKINUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
Biological Half-life PHARMACOKINETIC
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966